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Background - There are only few prospective data on blood pressure control in patients with chronic renal failure with the direct renin inhibitor 
aliskiren in a daily practice setting available.
Methods - In the non-interventional 3A Registry patients were eligible for inclusion in whom the physician had decided to modify the 
antihypertensive therapy. This included treatment with the direct renin inhibitor aliskiren or an ACE inhibitor (ACE-I)/angiotensin receptor blocker 
(ARB) or agents not blocking the renin-angiotensin-system (RAS), alone or on top of an existing drug regimen. Patients were prospectively followed 
for one year. Here we report the results of the prespecified subgroup with eGFR < 60 ml/min/1.73m2 (CKD-EPI)
Results - Of the 14841 patients recruited by 923 physicians in Germany in 2008 and 2009, 3254 patients had an eGFR < 60ml/min. Patients 
with reduced eGFR on the aliskiren containing regimen had significantly higher baseline blood pressure (BP) and diabetes (40% vs 36% vs 28%, 
p<0.0001). The following results in the 3 groups with reduced eGFR were obtained: 
Office
Blood pressure (BP)
(N=3254)
Aliskiren containing regimen
(N=2321)
ACE-I/ARB containing regimen
(N=555)
No RAS blockade
containing regimen (N=378)
p-value
(systolic/
diastolic)
BP at baseline (mmHg) 158+21/88+12 153+21/87+12 153+19/87+11 <0.001/<0.05
1 year follow up BP 
(mmHg)
138+16/80+9 137+17/80+9 136+15/80+8 <0.05/0.73
mean reduction in BP 
(mmHg)
20.1+22/8.0+12 15.8+23/6.5+12 17.4+20/ 6.7+12 <0.001/0.05
mean reduction in BP (%) 11.6+13/7.8+14 9.1+14/6.2/14 10.4+12/6.7+14 <0.001/0.07
serum creatinine change 
(mg/dl)
doubling of serum 
creatinine (%)
-0.05+2.4
1.7%
-0.05+ 2.6
1.9%
-0.4+2.1
1.5%
0.21
0.88
Serum potassium
Change (mmol/l)
>5.5 mmol/l (%)
>6.0 mmol/l (%)
0.0+2.4
7.4%
2.4%
-0.2+0.7
6.2%
1.9%
0.1+0.7
7.4%
1.1%
0.16
0.86
0.66
Conclusions:  In this large real life registry in hypertensive patients with reduced renal function, patients with an aliskiren-containing regimen 
showed better blood pressure reductions than patients without RAS-blockade, or an ACE-I/ARB-containing regimen, No difference in serious safety 
issues with respect to renal function or serum potassium were observed between the 3 groups.
